Predictions
Opko Health Inc.
Start price
Target price
Perf. (%)
€1.14
27.12.22
27.12.22
-
27.12.23
27.12.23
11.81%
24.04.23
24.04.23
Risky Investment
Mirati Therapeutics Inc.
Start price
Target price
Perf. (%)
€47.20
07.12.22
07.12.22
-
07.12.23
07.12.23
-16.53%
10.12.22
10.12.22
Risky Investment
Syneos Health, Inc.
Start price
Target price
Perf. (%)
€26.12
04.11.22
04.11.22
-
04.11.23
04.11.23
23.91%
10.11.22
10.11.22
Risky Investment
Medpace Holdings Inc
Start price
Target price
Perf. (%)
€218.90
25.10.22
25.10.22
€190.00
25.10.23
25.10.23
11.47%
26.10.23
26.10.23
Could be worthwhile Investment >10% per year
Invitae Corp
Start price
Target price
Perf. (%)
€2.14
16.10.22
16.10.22
-
16.10.23
16.10.23
-3.57%
18.02.23
18.02.23
Risky Investment
Invitae Corp
Start price
Target price
Perf. (%)
€2.47
27.09.22
27.09.22
-
27.09.23
27.09.23
-13.02%
15.10.22
15.10.22
Risky Investment
Blueprint Medicines Corp
Start price
Target price
Perf. (%)
€74.46
07.09.22
07.09.22
€100.00
31.12.24
31.12.24
-29.49%
05.05.23
05.05.23
Could be very worthwhile Investment >20% year
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€208.80
07.09.22
07.09.22
€300.00
31.12.24
31.12.24
-33.67%
30.05.24
30.05.24
Could be very worthwhile Investment >20% year
Glaukos Corp
Start price
Target price
Perf. (%)
€58.00
07.09.22
07.09.22
€63.00
07.09.23
07.09.23
-8.62%
08.05.23
08.05.23
Could be worthwhile Investment >10% per year
Invitae Corp
Start price
Target price
Perf. (%)
€2.76
02.09.22
02.09.22
-
02.09.23
02.09.23
-10.51%
27.09.22
27.09.22
Could be very worthwhile Investment >20% year
Invitae Corp
Start price
Target price
Perf. (%)
€3.32
26.08.22
26.08.22
-
26.08.23
26.08.23
-17.03%
03.09.22
03.09.22
Could be very worthwhile Investment >20% year
Mirati Therapeutics Inc.
Start price
Target price
Perf. (%)
€76.50
21.08.22
21.08.22
€230.00
21.08.23
21.08.23
6.54%
04.09.22
04.09.22
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€214.90
21.08.22
21.08.22
€87.00
21.08.23
21.08.23
-3.44%
04.09.22
04.09.22
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Invitae Corp
Start price
Target price
Perf. (%)
€3.50
21.08.22
21.08.22
€1.00
21.08.23
21.08.23
-21.28%
04.09.22
04.09.22
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
PTC Therapeutics Inc.
Start price
Target price
Perf. (%)
€51.50
16.08.22
16.08.22
-
16.08.23
16.08.23
-27.77%
16.08.23
16.08.23
Neurocrine Bioscience
Start price
Target price
Perf. (%)
€104.86
16.08.22
16.08.22
-
16.08.23
16.08.23
-6.73%
16.08.23
16.08.23
Global Blood Therapeutics Inc
Start price
Target price
Perf. (%)
€64.36
10.08.22
10.08.22
-
10.08.23
10.08.23
6.49%
10.08.23
10.08.23
Amicus Therapeutics Inc.
Start price
Target price
Perf. (%)
€12.10
10.08.22
10.08.22
-
10.08.23
10.08.23
3.34%
10.08.23
10.08.23
Invitae Corp
Start price
Target price
Perf. (%)
€2.86
12.07.22
12.07.22
€2.10
12.07.23
12.07.23
-54.35%
11.03.23
11.03.23
Could be worthwhile Investment >10% per year
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Bluebird Bio Inc.
Start price
Target price
Perf. (%)
€3.48
08.06.22
08.06.22
-
08.06.23
08.06.23
-14.83%
16.04.23
16.04.23
Risky Investment
Bluebird Bio Inc.
Start price
Target price
Perf. (%)
€2.81
30.05.22
30.05.22
-
30.05.23
30.05.23
23.85%
08.06.22
08.06.22
Risky Investment